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Abstract
RNA viruses such as poliovirus have high mutation rates, and a diverse viral population is likely required for full virulence.
We previously identified limitations on poliovirus spread after peripheral injection of mice expressing the human poliovirus
receptor (PVR), and we hypothesized that the host interferon response may contribute to the viral bottlenecks. Here, we
examined poliovirus population bottlenecks in PVR mice and in PVR mice that lack the interferon a/b receptor (PVR-IFNAR
2/2),
an important component of innate immunity. To monitor population dynamics, we developed a pool of ten marked
polioviruses discriminated by a novel hybridization-based assay. Following intramuscular or intraperitoneal injection of the ten-
virus pool, a major bottleneck was observed during transit to the brain in PVR mice, but was absent in PVR-IFNAR
2/2 mice,
suggesting that the interferon response was a determinant of the peripheral site-to-brain bottleneck. Since poliovirus infects
humans by the fecal–oral route, we tested whether bottlenecks exist after oral inoculation of PVR-IFNAR
2/2 mice. Despite the
lack of a bottleneck following peripheral injection of PVR-IFNAR
2/2 mice, we identified major bottlenecks in orally inoculated
animals, suggesting physical barriers may contribute to the oral bottlenecks. Interestingly, two of the three major bottlenecks
weidentifiedwere partiallyovercome bypre-treatingmicewithdextransulfate sodium, which damagesthe colonicepithelium.
Overall, we found that viral trafficking from the gut to other body sites, including the CNS, is a very dynamic, stochastic process.
We propose that multiple host barriers and the resulting limited poliovirus population diversity may help explain the rare
occurrence of viral CNS invasion and paralytic poliomyelitis. These natural host barriers are likely to play a role in limiting the
spread of many microbes.
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Introduction
RNA viruses undergo error-prone replication and exist as
quasispecies due to the high error rate of RNA-dependent RNA
polymerases (RdRp). Within these complex viral populations,
genomes can differ by one to many nucleotides resulting from
approximately one mutation incorporated per 10,000 nucleotides
[1,2,3]. For poliovirus, a mutant virus with a high fidelity RdRp
attenuated the virus in mice suggesting that a diverse quasispecies
is required for full virulence [4,5]. Genetic recombination also
contributes to quasispecies diversity, and has been detected in
poliovirus isolated from patients with paralytic poliomyelitis [6].
Mutation and genetic recombination may contribute to greater
viral population diversity leading to increased virulence [1,6,7].
Poliovirus is an enterovirus spread by fecal-oral transmission
and can cause poliomyelitis in humans. Only ,1% of people
infected with poliovirus develop paralytic poliomyelitis from viral
invasion of the central nervous system (CNS) [8,9,10]. Reversion
of the live-attenuated Sabin oral polio vaccine (OPV) by mutation
or recombination occurs rather frequently, but only causes
vaccine-associated paralytic poliomyelitis (VAPP) in a very small
percentage (0.0001%) of people that receive OPV [11,12,13,14].
The reason for such a low incidence of paralytic poliomyelitis and
VAPP remains unclear. Interestingly, in human VAPP patients,
viral isolates found in the CNS are a minor subset of those found
in feces, suggesting viral transit from the gut to the CNS may be
difficult in humans [15].
Poliovirus receptor (PVR)-expressing mice are susceptible to
poliovirus via intravenous, intraperitoneal, intracerebral, and
intramuscular routes [16,17,18]. Following intramuscular injec-
tion, poliovirus traffics to the CNS by retrograde neuronal
transport [19,20]. Intravenously injected poliovirus is thought to
reach the CNS by the blood route, independent of the presence of
PVR [21]. Intraperitoneally injected poliovirus may reach the
CNS by blood or neural routes. However, these injection models
may not mimic the natural fecal-oral route of infection since PVR
mice are not orally susceptible. Recently, PVR mice lacking the
interferon a/b receptor (PVR-IFNAR
2/2), a major component of
innate immunity, demonstrated oral susceptibility to poliovirus
[22,23]. Oral poliovirus infection in PVR-IFNAR
2/2 mice
resulted in dissemination of virus to many tissues such as
esophagus, nasopharynx-associated lymphoid tissue, small intes-
tine, spinal cord, and plasma, as measured by viral titer assay [23].
Viral titers in PVR-IFNAR
2/2 mice were typically 100 to 10,000-
fold higher than titers in PVR mice expressing IFNAR. Here, we
use PVR-IFNAR
2/2 mice to measure bottlenecks faced by the
viral population during trafficking inside a host.
PLoS Pathogens | www.plospathogens.org 1 June 2008 | Volume 4 | Issue 6 | e1000082Previously, we identified bottlenecks in PVR mice that limited
poliovirus population diversity after peripheral injection by
intravenous (IV), intraperitoneal (IP), and intramuscular (IM)
routes. An artificial quasispecies of four viruses with distinct
genomic restriction enzyme site tags were injected, and upon
disease onset, brains contained an average of 1.7 input viruses
suggesting that an intra-host bottleneck was encountered during
trafficking to the CNS [24]. Barriers encountered during spread of
microbes are common for many pathogens. Bottlenecks have been
described for plant RNA viruses [25], fungi [26], and bacteria such
as Salmonella and Yersinia [27,28,29]. Interestingly, the picornavirus
foot-and-mouth disease virus, may encounter inter-host and intra-
host bottlenecks [30,31,32].
In this study, we introduce a new system for monitoring viral
quasispecies trafficking in a murine host orally susceptible to
poliovirus. We developed a hybridization-based assay for detection
of a population consisting of ten marked viruses. To corroborate
our previous work, we examined viral trafficking following
peripheral injection of PVR mice vs. PVR-IFNAR
2/2 mice. In
addition, we orally inoculated PVR-IFNAR
2/2 mice to follow
viral trafficking from the initial inoculation site, the oral cavity, to
the gastrointestinal (GI) tract, blood, and brain. We identified
several bottlenecks that limit poliovirus spread following oral
inoculation, and found means of overcoming some of these
barriers by use of a colon-damaging agent.
Results
A novel viral population diversity assay
Bottlenecks were previously studied using restriction enzyme site
markers in the genomes of four distinct viruses; however, this assay
was labor intensive and only included four pool members [24]. To
overcome these drawbacks, we developed a more streamlined
assay based on signature-tagged mutagenesis technology used in
bacterial pathogenesis studies [33]. Hybridization-based detection,
96-well format, and an increased number of pool members are
advantages of the new assay.
The artificial quasispecies pool of ten members was engineered
by incorporating silent mutations into the VP3 capsid-coding
region of the genome, and oligonucleotide probes were designed
for specific recognition of each variant (Figure 1A, Figure S1). To
determine the specificity of the new assay, HeLa cells were infected
with individual viruses or a pool of all ten viruses, RNA was
isolated after one replication cycle, and RT-PCR products derived
from the RNA were blotted on a nylon membrane using a 96-well
vacuum manifold. Oligonucleotide probes were
32P-labeled and
hybridized to each blotted membrane individually (Figure 1B).
Each blot was hybridized with only one labeled probe; therefore,
ten blots were performed for each sample. Figure 1C displays the
probe hybridization specificity following infection of HeLa cells
and probing all samples with each probe. All oligonucleotide
probes proved specific for their cognate virus. To ensure the
viruses had no detectable growth defects, single-cycle growth
curves were performed for each virus and no differences in growth
were observed (Figure S2). Additionally, a serial passage
competition experiment was performed by infecting HeLa cells
with a mixture of the ten viruses and then passaging the virus
mixture five times, followed by assessment of input virus loss over
time. All ten viruses were maintained throughout the passages, and
therefore, no major growth defects of the marked viruses were
detected in vitro (Figure 1D). For each hybridization assay,
normalization was performed to eliminate cross-reactivity of
nonspecific probes (Figure 1E). Perfectly matched product (PCR
product specific for the probe) and mismatched products (all PCR
products except for the one specific for the probe) were loaded on
each membrane as controls. The image intensity level of the blots
was adjusted until the mismatched product signal became
undetectable, revealing only legitimate signals.
The bottleneck between the periphery and brain
following injection is reduced in PVR-IFNAR
2/2 mice
Validation of the new hybridization assay confirmed the
bottleneck effect observed in previous experiments [24]. PVR
mice were inoculated with 2610
7 plaque-forming units (PFU) of
a pool of all ten viruses (2610
6 PFU each; viruses 2 through 11)
by intramuscular (IM) or intracerebral (IC) injection. Brains of
mice inoculated with 2610
7 PFU by the IC route contained
most, if not all, input viruses upon disease onset; however, the
brains of IM-injected mice contained 10% to 30% of the input
viruses (Figure 2A, 2B). For IM-injected mice, all ten viruses
were present at the inoculation site, muscle. Brains of PVR mice
inoculated by the intraperitoneal (IP) route with 1610
8 PFU of
the ten-virus pool contained only 10% of the input viruses. These
experiments validated the new assay and confirmed our previous
results [24].
Next, we measured viral population diversity in PVR-
IFNAR
2/2 mice, which are hyper-susceptible to poliovirus
[22,23]. We hypothesized that innate immunity may contribute
to the bottleneck, and therefore, we predicted increased population
diversity in the brains of PVR-IFNAR
2/2 mice. PVR-IFNAR
2/2
mice were injected intramuscularly with 2610
7 PFU of the ten-
member pool. As shown in Figure 2A and 2B, the brain
bottleneck was greatly diminished in PVR-IFNAR
2/2 mice, with
40% to 100% of the input viruses detectable in the brain. In fact,
the brains of IM-injected PVR-IFNAR
2/2 mice contain an
average of 70% of the input viruses, a result comparable to PVR
mice injected IC with 2610
7 PFU. Similarly, brains of IP-
inoculated PVR-IFNAR
2/2 mice contained 80% of the input
viruses. The diminished bottleneck in PVR-IFNAR
2/2 mice may
be the result of increased peripheral titers in PVR-IFNAR
2/2
mice, essentially increasing the viral dose, physical barrier
differences caused by the lack of IFNAR, such as alteration of
neurons or the blood-brain barrier that affect viral trafficking, or,
Author Summary
RNA viruses are highly error prone, and can use their
replication infidelity to adapt to complex environments
within an infected host. However, viral populations may
experience bottlenecks, which limit their diversity and
potentially reduce their virulence. We hypothesized that
natural barriers may limit the spread of RNA viruses within
an infected host. To test this hypothesis, we engineered a
pool of ten marked polioviruses identifiable by a novel
assay, infected susceptible mice by injection or oral
inoculation, and determined the percentage of the ten
viruses that successfully spread to various body sites,
including the brain. We found that, on average, only 10%–
20% of the input viruses were found in most tissues,
suggesting that barriers prevented the spread of the
whole population. The importance of one such physical
barrier, the colonic epithelium, was demonstrated in
experiments where the colon was damaged prior to oral
inoculation. Under these conditions, 30%–50% of the input
viruses successfully spread to various body sites. We
propose that host barriers limit viral spread, and this could
possibly explain the rare incidence of paralytic poliomy-
elitis due to central nervous system invasion.
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virus(es) to enter the brain contributes to the bottleneck observed
in PVR mice. To determine whether the amount of virus entering
the brain influences viral diversity, PVR and PVR-IFNAR
2/2
mice were inoculated by the IC route with a low dose of the ten
virus mixture, 2610
3 PFU, which corresponds to 200 PFU of
Figure 1. A new hybridization-based quasispecies detection assay. (A) Poliovirus genome highlighting VP3 region of P1 where point
mutations were incorporated by site-directed mutagenesis (bold, underlined) to distinguish each of the ten viruses from one another. The amino acid
sequence and the wild-type poliovirus genome sequence of the region are shown. Note: Wild type is virus #1, and was not included in our ten-virus
pool due to cross hybridization (data not shown). (B) Strategy for the assay. (C) Blot showing the specificity of each labeled probe for its respective
viral RT-PCR product. HeLa cells were infected with each individual virus, and samples were processed as described in B. (D) Serial passage
competition experiment. HeLa cells were infected with equal amounts of each of the ten viruses, and amplified virus was harvested after a single
cycle of replication and used to infect fresh cells. This cycle was repeated for a total of five passages to rule out viral growth defects. (E) Normalization
process to eliminate probe cross-reactivity. Signal intensity levels were adjusted such that mismatch (MM; all PCR products except for the one specific
for the probe) signal was no longer detectable, and perfect match (PM; PCR product specific for the probe) was used as a positive control. Any visible
dots, regardless of intensity, were counted as positive in diversity assays (see circled example).
doi:10.1371/journal.ppat.1000082.g001
Host Barriers Restrict Viral Trafficking
PLoS Pathogens | www.plospathogens.org 3 June 2008 | Volume 4 | Issue 6 | e1000082each pool member. Using this low input dose, viral diversity was
low in the brains of both PVR and PVR-IFNAR
2/2 mice (13%
and 24% of input viruses present, respectively) (Figure 2B). These
results suggest that the bottleneck we observe is affected by the
quantity of virus entering the brain.
The viral bottlenecks we observe are independent of selective
advantages possessed by a particular marked virus. Based on a
compilation of 479 hybridization signals, all ten viruses were
approximately equally represented in a variety of tissues from over
25 mice, although virus 3 showed reduced representation, possibly
indicating a slight growth defect (Figure 1D; Figure S3). However,
statistical analysis revealed that none of the viruses, including virus
3, were significantly under- or over-represented in mouse tissues
(p=0.07 to p=1, Student’s t test). This apparent random
sampling of population members was also observed in our
previous study [24].
Bottlenecks exist following oral inoculation of PVR-
IFNAR
2/2 mice
Unlike PVR mice, PVR-IFNAR
2/2 mice are orally susceptible
to poliovirus [22,23]. Although the peripheral site-to-brain
bottleneck was reduced in PVR-IFNAR
2/2 mice (Figure 2A,
2B), we sought to determine whether bottlenecks exist following
oral inoculation. Because the gut is a complex environment
composed of many unique cell types and processes, barriers to
viral spread may be encountered in PVR-IFNAR
2/2 mice despite
the hyper-susceptibility of these animals to poliovirus. We orally
inoculated PVR-IFNAR
2/2 mice with 2610
7 PFU of a mixture
of the ten-member virus pool. Following oral inoculation, PVR-
IFNAR
2/2 mice developed encephalitis rather than paralysis
observed in injected mice, and disease onset was delayed, with
symptoms developing on days five through ten or later, in
agreement with published data [23]. Feces were harvested daily
Figure 2. Viral diversity in injected PVR mice and PVR-IFNAR
2/2 mice. (A) PVR mice were injected intracerebrally (IC) and intramuscularly
(IM) with 2610
7 PFU of the ten-virus pool, tissues were harvested upon disease onset, and viral diversity in brain and muscle was determined and
compared to PVR-IFNAR
2/2 mice injected IM. Blots derived from two representative viral-derived RT-PCR products are shown per condition, with
specific probes numbered along the top. (B) Number of input viruses present in tissues from IM, intraperitoneally (IP), or IC-injected PVR mice and
PVR-IFNAR
2/2 mice. Data from experiments shown as representative examples in panel A and additional experiments, are compiled to display results
from at least 5 mice per condition. PVR mice, gray squares; PVR-IFNAR
2/2 mice, open circles. Horizontal bars denote the average for each group. The
average time of symptom onset (day post-inoculation) +/2 standard deviation is shown at the bottom. The p values from Student’s t test are shown:
values above the graph compare viral diversity among indicated samples, values below the graph compare disease onset time among indicated
samples. An asterisk denotes statistical significance (p,0.05).
doi:10.1371/journal.ppat.1000082.g002
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onset. Viruses isolated from stomach, small intestine, colon, feces,
and blood were amplified for approximately three replication
cycles in HeLa cells to increase detection, as the detection limit of
the hybridization assay is ,5,000 PFU (data not shown). In vitro
amplification does not significantly affect diversity of virus
extracted from tissues. For example, in the brain, where viral
titers were high enough to perform the hybridization assay with or
without amplification, viral diversity was equivalent in amplified
and unamplified viral stocks (data not shown). Therefore, in vitro
amplification allows detection without significantly altering the
composition of the viral population.
Three major poliovirus bottlenecks were observed in orally
inoculated PVR-IFNAR
2/2 mice. First, a major bottleneck
occurred between the inoculation site (mouth) and gut tissues
(Figure 3). Gut tissues were harvested upon disease onset, and
lumenal contents were removed. An average of approximately
20% of input viruses were present in the stomach, small intestine,
and colon (Figure 3B). Notably, virus was detectable in the
stomach late in infection upon disease onset, suggesting that non-
input replicating virus was present. These results support the
notion that poliovirus is resistant to stomach acid and digestive
enzymes, although it is possible that viruses entered the
bloodstream and re-seeded organs later in the disease course.
Interestingly, viruses found in one GI tract tissue did not always
correlate with those detected in other GI tract tissues within the
same animal (e.g. mouse 9-1, Figure 3).
Second, a major bottleneck occurred between the mouth and
blood (Figure 3). It is unclear how poliovirus enters the
bloodstream, with evidence supporting upper GI and lower GI
routes [34,35,36]. We found that less than 50% of mice had
detectable virus in blood harvested at disease onset, with an
average of 9% of input viruses present (Figure 3). Because it is
likely that viremia occurred earlier in the disease course, we
assessed viral population diversity in blood from a separate set of
animals bled at several time points. Similar to the results obtained
by sampling blood at disease onset, less than 60% of day three
blood samples contained detectable virus, with an average of 17%
of input viruses present (data not shown).
Third, a major bottleneck occurred between inoculation site
and brain, with an average of 21% of input viruses detected in the
brain, harvested upon disease onset (Figure 3). Surprisingly, viruses
found in the brain did not always correlate with those detected in
other tissues within the same animal.
Interestingly, the timing of disease onset and viral population
diversity were associated, such that earlier disease onset correlated
with higher diversity. Mice developing symptoms prior to day seven
had 3.3-fold (p=0.025) more input viruses in the brain than those
developing symptoms after day seven, according to mean viral
diversity comparison (Figure 3B). Higher diversity was also observed
in blood and gut tissues of the early onset mice, with 9-fold higher
diversity in blood (p=0.042), and 2.1 to 3.3-fold higher diversity in
gut tissues (stomach, small intestine, and colon; p,0.05).
Passage through the GI tract is not difficult for poliovirus
With the finding that major bottlenecks occurred during viral
trafficking from the mouth to other mouse tissues, it became
important to determine whether transit through the gut environ-
ment is difficult for poliovirus populations. Interestingly, only a
minimal bottleneck occurred between inoculation site (mouth) and
feces (Figure 3A & 3B). For the population diversity assay, we
analyzed fecal samples collected at 24 hours post-inoculation
because relatively high viral titers were detected at this time. On
average, more than 80% of input viruses were detected in feces
(Figure 3B & 6A). Many of the mice (5/13) shed all ten input
viruses in feces.
Because viral diversity was high in feces, we sought to determine
whether the 24-hour fecal samples contained replicated virus, non-
replicated/input virus, or both. First, we monitored viral transit
time through the GI tract by measuring fecal titers at several time
points, and transit time of a dye. Mice were orally inoculated with
2610
7 PFU of poliovirus, or Evan’s Blue dye as a tracer. Fresh
feces were harvested at regular intervals. Viral titers were
determined by standard plaque assay using HeLa cells, and transit
time of Evan’s Blue was determined by scoring the relative dye
intensity of fecal samples. As shown in Figure 4A, very high fecal
titers were present at 2 hours post-inoculation for some animals.
Since this time point is within the eclipse period of the viral
replication cycle (see Figure S2), we presumed that virus shed at
2 hours post-inoculation was input/non-replicated virus. Viral
titers remained relatively high from 5–12 hours post-inoculation,
and then declined at later time points. This rise and decline of viral
titers correlated well with the transit time of Evan’s Blue dye
through the mouse GI tract (Figure 4A).
Although the results from the fecal virus kinetics study suggested
that virus shed at early time points is input/non-replicated virus,
the presence of replicated virus could not be excluded; therefore,
we monitored the transit of light-sensitive poliovirus to directly
measure the amount of replicated vs. non-replicated virus present
in feces. Poliovirus grown in the presence of neutral red (NR) is
sensitive to inactivation by light exposure due to dye incorporation
and concentration in virions [37,38,39]; hence, these viruses must
be handled in the dark, using a red safety light. Upon replication
in the absence of NR, viruses lose this light sensitivity. Therefore,
the presence or absence of light-sensitive poliovirus in feces was
utilized to monitor whether replication had occurred in the GI
tract of orally inoculated mice. In the dark, mice were orally
inoculated with 2610
7 PFU of light-sensitive NR-poliovirus, and
feces were harvested in the light or in the dark. As a control, 6-
hour feces harvested in the dark were subjected to titer analysis in
light vs. dark conditions. The non-light exposed samples
demonstrated high titers: viable virus titers were ,40% of non-
NR poliovirus titers harvested at the 6 hour time point in
Figure 4A. We presume that these NR-virus titers were not 100%
of the non-NR titers due to intrinsic variability in the animal
experiments and/or subtle defects in NR-containing virions. Upon
exposure to light, ,0.1% of the non-NR poliovirus titer was
obtained, indicating a very low level of light-insensitive viruses in
the population (Figure 4B, right). Fecal samples exposed to light
contained negligible viral titers until after 10 hours post-inocula-
tion, suggesting that prior to 10 hours, feces contain input/non-
replicated virus (Figure 4B, left). However, at 24 hours post-
inoculation, feces contained light-insensitive/replicated virus,
although only ,14% of the non-NR poliovirus titer was obtained.
Therefore, the 24-hour fecal samples used for our population
diversity analysis contained a mixture of replicated and non-
replicated/input virus.
Effect of colonic mucosal damage and antacid
administration on viral titers
We hypothesized that the colonic mucosal epithelium and/or
stomach acidity may create barriers that contribute to viral
bottlenecks. Therefore, we treated mice with agents that damage
the colonic mucosa or neutralize stomach acid and determined the
effects on poliovirus titer and diversity. Damage to the colonic
mucosa was induced by treating mice with dextran sulfate sodium
(DSS) in drinking water. DSS directly damages colonic epithelia
resulting in ulceration, immune infiltration, and bloody feces
Host Barriers Restrict Viral Trafficking
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blood (Figure 5C), and brain (Figure 5D) following oral
inoculation performed +/2 DSS pre-treatment. High-dose (5%)
DSS treatment increased 72-hour fecal titers 56-fold
(p=0.000163). Day one fecal titers were 16-fold higher in 5%
DSS-treated mice compared to untreated mice. Blood titers for
5% DSS-treated mice were increased 66-fold, and virus was
detected in the blood of all 5% DSS-treated mice (Figure 5C)
compared to untreated mice, where less than 50% of animals had
detectable virus in blood. Treatment with 3% DSS did not have
an effect on viral titers suggesting that 3% DSS may not induce
sufficient damage.
We next assessed the role of stomach acid in establishing the
poliovirus bottleneck. The mouth-to-feces bottleneck is minor
since the majority of the ten input viruses were detected in feces.
However, Ohka and colleagues showed that sodium bicarbonate,
an acid-neutralizing agent, increased poliovirus titers in a ligated
stomach model following oral inoculation of PVR-IFNAR
2/2
Figure 3. Viral diversity in orally inoculated PVR-IFNAR
2/2 mice. Mice were orally inoculated with 2610
7 PFU of the ten-virus pool, and
tissues were harvested upon disease onset. (A) Blot results for five representative orally inoculated PVR-IFNAR
2/2 mice. Mouse 9-3 (bottom) did not
develop disease during the ten-day post-inoculation time course. Sm.Int.=small intestine. Asterisks indicate samples that were the product of viral
amplification in HeLa cells to improve detection (see text and Materials and Methods). (B) Compilation of input viruses found in each tissue at disease
onset and found in feces collected on day one post-inoculation. Mice are arranged in order of earliest to latest disease onset (NS=no symptoms at
harvest on day ten). Each box depicts a particular virus based on blot results. ND= not determined.
doi:10.1371/journal.ppat.1000082.g003
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2/2 mice with a
virus/5% sodium bicarbonate mixture. Our results revealed no
titer differences between sodium bicarbonate-treated and untreat-
ed animals (Figure 5A–D).
Colonic mucosal damage increases population diversity
in GI tract and blood, but not brain
Since 5% DSS-treated poliovirus-infected mice demonstrated
increased viral titers, we reasoned that viral population diversity
may be increased in these mice. Therefore, we performed the viral
population diversity assay for samples from 5% DSS-treated,
orally inoculated PVR-IFNAR
2/2 mice. As expected, viral
diversity in feces was high for all mice, regardless of treatment
(Figure 6). Viral diversity in the stomach of 5% DSS-treated mice
increased 1.8-fold (p=0.0218), diversity in the small intestine
increased 2.2-fold (p=0.00865), and diversity in the colon
increased 2.8-fold (p=0.0000497) compared to untreated controls
(Figure 6). Additionally, viral diversity in blood increased 3.5-fold
(p=0.0101). Interestingly, viral diversity in the brain was
unaffected by DSS treatment (Figure 6A). Again, we found that
viruses present in the brain do not necessarily correlate with those
present in blood or gut tissues (Figure 6B). Viral diversity in tissues
of mice treated with 3% DSS or sodium bicarbonate did not differ
from untreated mice (Figure 6A).
Comparison of viral titer vs. viral population diversity
unmasks bottlenecks following oral inoculation
Initially, one might assume that viral titer and viral diversity are
linked, with high titer sites containing high population diversity,
and vice versa. However, this is not the case, especially when
bottlenecks are present [25,44]. Figure 7 compares viral titer vs.
diversity for feces, blood, and brain viruses from untreated mice
orally inoculated with the ten-virus mixture. Fecal samples
contained low to moderate titers of ,5–300 PFU/mg, but
contained moderate to high population diversity. Titer and
diversity may be linked before a major bottleneck is encountered,
as in feces, in which higher titers correlate with higher diversity.
These results confirmed that the bottleneck between mouth and
feces is minor. Brain samples had the highest titers (,2,000–
100,000 PFU/mg), but contained low diversity, which is charac-
teristic of a major bottleneck. We propose that entry into the brain
is difficult, but once in the brain, founder viruses undergo robust
replication. Blood samples had low to moderate titers (,1–
700 PFU/mg) and low diversity. Therefore, our data confirm that
titer and diversity are not linked following bottlenecks.
Discussion
We have developed a new diversity assay that has allowed us to
uncover barrierstoviral trafficking that would bemissed bystandard
viral titer assays. Using our hybridization-based assay, we demon-
strated bottleneck barriers by monitoring marked polioviruses.
We confirmed a previously observed bottleneck between
peripheral injection sites and brain (Figure 2). As before, random
sampling was revealed, in which no pool member had an apparent
selective advantage over the others (Figure 1D; Figure S3). The
previous assay employed four viruses, and one to three were found
in the brain (average ,50%) following IM injection [24]. Here we
found that, on average, ,20% of our ten marked viruses reached
the brain, suggesting that this bottleneck was more severe than that
previously observed. One possible explanation is that the previous
study was performed using ICR-PVR mice [18], while this study
was performed using C57/BL6-PVR mice [45]. Additionally, the
observed increase in bottleneck severity could be a result of our
increased artificial quasispecies sample size.
Because interferons (IFN) play an important role in controlling
viral infections, prior to this study, we proposed that the IFNa/b
response may contribute to viral bottlenecks. In PVR-IFNAR
2/2
mice, the bottleneck following IM or IP injection was largely absent
withanaverageof70%or80%ofinputvirusesdetectedinthebrain,
respectively. In fact, direct injection of a large inoculum
(2610
7 PFU) of the virus pool into the brains of PVR mice resulted
in an average of 76% of input viruses detected in the brain,
confirmingtheabsenceofamajorbottleneckinperipherally-injected
PVR-IFNAR
2/2 mice. We propose several possible reasons for the
diminished bottleneck in peripherally-injected PVR-IFNAR
2/2
mice: 1) The first viruses to enter the brain in PVR mice established
an anti-viral state which limited the spread of later viruses, resulting
in a bottleneck effect. The lack of IFNa/b response in PVR-
IFNAR
2/2 mice, therefore, facilitated higher brain diversity. 2)
Increased peripheral titers in hyper-susceptible PVR-IFNAR
2/2
mice may have essentially increased the poliovirus dose. This effect
Figure 4. Kinetics of poliovirus shedding in feces. (A) Mice were
orally inoculated with 2610
7 PFU of poliovirus or a solution of 8%
Evan’s Blue dye to trace transit through the GI tract. Fresh feces were
harvested from individual mice at the indicated time points, and viral
titers (filled circles) or Evan’s Blue Score (open squares) were
determined for 2–5 mice per time point. Titer averages are indicated
by the horizontal lines. Evan’s Blue Score was determined by assessing
the level of blue dye in fecal samples (see Materials and Methods). ND,
not detected (below the detection limit). (B) Neutral red (NR) light-
sensitive poliovirus was used to measure input/non-replicated vs.
replicated virus in feces. Mice were orally inoculated with 2610
7 PFU of
NR-poliovirus in the dark, and feces were harvested in the dark (right
side, gray bars) or in the light (left side, white bars) at the indicated time
points. Fecal virus titers were determined in HeLa cells under light or
dark conditions, and NR virus titers were divided by non-NR virus titers
from the same time points (in panel A) to generate normalized titer
values, expressed as ‘‘% of Non-NR Virus Titer’’, an indication of the viral
replication level prior to shedding in feces.
doi:10.1371/journal.ppat.1000082.g004
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2/2 mice since our previous work
determined it was very difficult to overcome the bottleneck by
increased dose in PVR mice [24]. 3) Physical barriers in PVR-
IFNAR
2/2micemayhavebeenalteredduetolackofthetypeIIFN
environment. Perhaps lack of IFNAR created differences in neurons
or the blood-brain barrier that may have contributed to higher viral
brain diversity in PVR-IFNAR
2/2 mice. Importantly, data from
our oral inoculation studies demonstrated a bottleneck exists
between mouth and brain in PVR-IFNAR
2/2 mice (Figure 3).
Therefore, the lack of the IFNa/b response in the brain was not the
sole cause for the diminished bottleneck in peripherally-injected
PVR-IFNAR
2/2 brains. Additionally, PVR and PVR-IFNAR
2/2
mice injected by the IC route with a low dose of the virus pool
(2610
3 PFU) demonstrated comparable low levels of viral diversity
in the brain (13% and 24% of input viruses, respectively). These
results suggest that viral diversity in the brain is governed by the
amount of virus that enters the brain, and that elevated peripheral
titers in injected PVR-IFNAR
2/2 mice contribute to the elevated
viral diversity in the brains of these animals.
Following oral inoculation of PVR-IFNAR
2/2 mice, poliovirus
moves through the GI tract without much difficulty. Relatively
high amounts of virus were shed in feces, including input/non-
replicated viruses and replicated viruses, depending on the
sampling time (Figure 4). Population diversity in feces was
relatively high with an overall average of 81% of input viruses
present (Figures 3 and 6A), suggesting only a minor bottleneck was
encountered during GI lumenal passage. Although we consider
this bottleneck minor, it could actually represent the successful
passage of just 0.025% (5610
3 PFU) of the input virus, which
would still allow detection of all pool members in our system.
Regardless, this mouth-to-feces bottleneck was minor in compar-
ison to other bottlenecks we observed.
Our experiments identified three major bottlenecks following
oral inoculation of PVR-IFNAR
2/2 mice: mouth-to-gut tissues,
mouth-to-blood, and mouth-to-brain. First, a major bottleneck
existed between the mouth and gut tissues. Of the ten viruses, an
average of 16% of input viruses were present in the stomach, and
19% of input viruses were present in the small intestine and the
colon (Figures 3 and 6). We presume that virus must be replicating
in these tissues to be detected late in infection when the tissues
were harvested (day 5–10). However, gut tissues could have been
re-seeded by virus in the blood.
Figure 5. Poliovirus titers from orally inoculated untreated, DSS-treated, and antacid-treated PVR-IFNAR
2/2 mice. Mice were left
untreated or were pre-treated with 3% or 5% dextran sulfate sodium (DSS) in drinking water for 3 or 5 days, respectively. A group of mice were then
infected with 2610
7 PFU of the ten-virus pool, in the presence or absence of an acid neutralizing agent, 5% NaHCO3. (A and B) Poliovirus titers,
expressed as plaque-forming units (PFU) per mg, in feces harvested on day 1 (A) or day 3 (B) from untreated, 5% and 3% DSS-treated, and 5%
NaHCO3-treated mice. Asterisk indicates statistically significant difference between untreated and 5% DSS treated mice (p,0.0002, Student’s t test).
(C) Poliovirus titers in blood collected at disease onset. (D) Poliovirus titers for brain collected at disease onset. Gray symbols=mice that developed
disease; white symbols=mice that did not develop disease by day 10 post-inoculation. ND, not detected. The detection limit for the titer assay is ,
1 PFU/mg. Averages are indicated by horizontal lines.
doi:10.1371/journal.ppat.1000082.g005
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Blood titers were moderate, but diversity was very low (avg.=9%
of input viruses) (Figures 3, 6, and 7). We are uncertain how the
virus is traveling from the inoculation site into the blood, but
possibilities include drainage from lymph, mucosal passage to the
blood, and entrance into the bloodstream at sites of mucosal
Figure 6. Viral diversity in tissues from orally inoculated untreated, DSS-treated, and antacid-treated PVR-IFNAR
2/2 mice. Samples
from the mice described in Figure 5 were subjected to the hybridization-based diversity assay. (A) Number of input viruses present, compiled from
the hybridization-based assay, in different tissues and feces from untreated, 5% and 3% DSS-treated, and antacid (5% NaHCO3)-treated PVR-IFNAR
2/2
mice. Averages are represented by horizontal lines. Asterisks indicate statistically significant differences between untreated and 5% DSS-treated mice
(p,0.05, Student’s t test; see text for exact p values). (B) Viral diversity in tissues of 5% DSS-treated mice. Shown here are individual viruses found in
each tissue at disease onset and feces collected on day one post-inoculation. Each box depicts a particular virus detected following hybridization of
probes, based on blot results. Mice are arranged in order of earliest to latest disease onset. It is likely that the first two mice, 9-6 and 9-4, succumbed
to DSS treatment rather than poliovirus since no virus was detected in the brain of these animals.
doi:10.1371/journal.ppat.1000082.g006
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infection [34,46,47].
Third, a prominent bottleneck existed between the mouth and
the brain. Viral trafficking between the mouth and brain could
have occurred through blood or neural routes. Historically,
poliovirus invasion of the brain has been presumed to occur
through the blood route because neutralizing antibodies are
protective and IV-injected radiolabeled virions readily enter the
murine brain [21,48,49]. However, viral trafficking in neurons
may also occur and contribute to pathogenesis [10,19,20,50].
Surprisingly, 93% of viruses found in the brain were present in
gut tissues of a given mouse, but only 35% were detected in blood
(Figure 3B). This suggests that a gut tissue-to-brain pathway was
involved in viral spread. Virus may have entered the blood from
gut tissues and trafficked to the brain, or virus may have infected
neurons associated with the GI tract and reached the brain by
retrograde transport. Trafficking via neurons has been demon-
strated by sciatic nerve transection experiments following
poliovirus infection [19,20]. Although our data did not definitively
discriminate between blood and neural routes, our data did show
that absolute match of blood and brain viruses was rare. In some
instances, there was no overlap between viruses present in the
brain and blood (Figure 3B, 9-6; Figure 5, 9-1). These results
indicated that virus may enter the brain by a non-hematogenous
route, such as neurons, that low-abundance viruses in blood
seeded the brain, or that virus found in the blood at disease onset
differed from the virus in the blood at earlier time-points.
Interestingly, the blood/brain virus mismatch was confirmed in
an experiment where blood was collected at day three post-
inoculation and upon disease onset, and then blood diversity was
compared with brain diversity. This experiment revealed that only
44% of viruses found in the brain are present in blood at day three
post-infection, suggesting that not all viruses may spread to the
brain via a blood route (data not shown). Aside from possible GI
neuronal trafficking, it is likely that virus moves into and out of
blood throughout infection by seeding other tissues with
subsequent re-seeding of the blood. In humans, it is thought that
a primary asymptomatic viremia may seed tissues, with a
subsequent secondary viremia contributing to minor or major
illness, which can lead to CNS invasion and paralytic poliomyelitis
[34,35,36].
Our results suggested that disease onset and viral diversity are
linked. Earlier disease onset correlated with greater viral diversity in
the gut tissues, blood, and brain. Mice that developed symptoms
before day seven had 3.3-fold (p=0.025) higher brain diversity than
those that developed symptoms later (Figure 3B). These early onset
mice also had higher blood diversity (9-fold, p=0.042) and gut
diversity (2.1–3.3 fold, stomach: p,0.05). Greater diversity upon
earlier onset was not simply due to a tissue sampling time bias,
because a separate study demonstrated very low population diversity
in tissues harvested on days one and three post-inoculation (Figure
S4). There are several possible explanations for the correlation of
disease onset and viral diversity. First, since high population diversity
and virulence are linked [4,5], higher viral diversity may contribute
to faster disease progression. Second, some component of host
immunity may have developed later in infection, which limited viral
replication, and ultimately, viral diversity.
Interestingly, two of the three major bottlenecks could be
overcome by pre-treating the mice with a colonic epithelial-
damaging agent, DSS. The first (mouth-to-gut tissues) and second
bottlenecks (mouth-to-blood) were affected by DSS treatment: gut
tissue and blood diversity increased ,2–3-fold and 3.5-fold,
respectively. Additionally, blood titers increased 66-fold in the
presence of colonic damage. Importantly, the mouth-to-brain
bottleneck was unchanged in DSS-treated mice compared to
untreated mice. These results suggest that either virus trafficked to
the brain via a non-blood route, which was unaffected by DSS
treatment, or virus trafficked to the brain via a blood route, but
spread to the brain was limited by another barrier, such as the
blood-brain barrier.
Viral titer and diversity were not linked after a bottleneck was
encountered (Figure 7). By monitoring diversity, we uncovered
limitations on viral trafficking that would be missed by viral titer
analysis. For example, blood and fecal titers were similar;
therefore, one might conclude that transit from the gut to blood
was not difficult. Our assay allowed us to conclude that a major
bottleneck exists since blood diversity was low. We presume that
virus was replicating in blood and/or other tissues that seed blood,
thus increasing the blood titer post-bottleneck encounter, resulting
in founder effects.
We found that viral population trafficking was a very dynamic,
stochastic process. Using virus 2 as an example, a given virus
might be present in all tissues (Figure 3, 9-1), in colon and feces
only (Figure 3, 9-2), in brain and feces only (Figure 3, 9-6), or in
other differing combinations. Similar random trafficking patterns
have been observed in several microbial systems, including animal
and plant viruses, bacteria, and fungi [25,26,27,28,29,30,31,32].
For highly mutable RNA viruses, host barriers likely play an
important role in shaping viral populations and determining
virulence [51].
The random distribution of viral populations makes predicting
VAPP (vaccine-associated paralytic poliomyelitis) impossible,
because a viral isolate from the CNS of one person may not
invade the CNS of another due to bottleneck effects and stochastic
trafficking. Notably, in human VAPP patients, fecal virus does not
always correlate with virus found in the CNS [15]. Perhaps
physical barrier disruption and/or a defective innate immune
response increased susceptibility to inadvertent poliovirus CNS
invasion in individuals afflicted with paralytic poliomyelitis. We
have shown that this artificial quasispecies system mimics the
stochastic poliovirus trafficking observed in humans, and can be
used to understand RNA virus population dynamics in an infected
host.
Figure 7. Bottlenecks revealed by comparing viral titer vs.
diversity. Samples from untreated, orally inoculated PVR-IFNAR
2/2
mice were compared by graphing viral titer (see Figure 5C–F) vs. the
number of input viruses present (see Figure 6A). Samples with 1–3
input viruses present experienced a severe bottleneck, samples with 4–
7 input viruses present experienced a partial bottleneck, and samples
with 8–10 input viruses present experienced a minimal bottleneck.
doi:10.1371/journal.ppat.1000082.g007
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Plasmid Construction
The ten viral plasmids (2 through 11) were made using silent
site-directed mutagenesis of the Mahoney serotype 1 viral cDNA
clone beginning with nucleotide 2425 and ending at 2443
(Figure 1A) [52]. Two unique silent restriction sites were added,
Bgl II at nucleotide 5601 and Mlu I at nucleotide 7550, in order to
facilitate cloning. Each PCR-generated region was confirmed by
sequencing (Sequencing Core, UT Southwestern Medical Center,
Dallas, TX).
Viruses and Cell Culture Infections
All poliovirus work was done in WHO-approved elevated BSL2/
poliovirusconditions.Cellcultureinfectionsandpropagationofvirus
was performed from a single poliovirus plaque using HeLa cells
grown in Dulbecco’s modified Eagle’s medium with 10% calf serum
as previously described [53]. For the viral serial passage experiment
(Figure 1D), the ten viruses were combined at equivalent amounts
and single-cycle infections beginning with a MOI of 0.1, were
performed as described [4]. Virus stocks were titered using plaque
assaysinHeLacellsaspreviouslydescribed [53]. A neutralred (NR)-
poliovirus stock was prepared by infecting HeLa cells with wild-type
poliovirus in the presence of 10 ug/ml neutral red (Sigma) in the
dark, using a red safety light [37,38,39]. NR-poliovirus stocks were
light inactivated by exposure to a fluorescent light bulb at a distance
of 3 inches for 10 minutes. The ratio of light-insensitive to light-
sensitive PFU in the NR-poliovirus stock was 1 to 1.27610
6.
Mice, Treatments, and Infections
All animal work was performed according to protocols
approved by the UT Southwestern Medical Center IACUC.
C57/BL6 PVR-Tg21 (PVR) mice and C57/BL6 PVR-
IFNAR
2/2 (PVR-IFNAR
2/2) mice were obtained from S. Koike
(Tokyo, Japan), and maintained in specific pathogen free
conditions [22]. Intramuscular (50 ml volume) and intracerebral
(15 ml volume) injections were done as previously described [4]
using 2610
7 PFU total (2610
6 PFU of each of the 10 viruses), or
2610
3 PFU total for low-dose IC injections. For intraperitoneal
injections, 1610
8 PFU total of the 10 viruses were injected in a
volume of 50 ml. It should be noted that inocula for all
experiments in this study were based on viral titers obtained using
HeLa cells. We have shown previously that poliovirus titers in
PVR-derived mouse embryo fibroblasts (PVR-MEFs) are approx-
imately 300-fold lower than those obtained in HeLa cells [4].
Therefore, in terms of poliovirus titers in mouse cells, mice were
actually inoculated with 6.67610
4 PFU for the ‘‘2610
7 PFU’’
inoculations. Oral inoculations were performed by dispensing
15 ml of virus, by pipette tip, in the mouth. Each mouse was
euthanized at first signs of disease, which included encephalitis,
ruffled fur, lethargy, and paralysis. In our experience, once
symptoms develop, the mice die within a day. For DSS treatments,
mice were pre-treated with DSS (molecular weight 36,000–50,000;
MP Biomedicals LLC, Solon, OH) in their drinking water prior to
oral inoculation [40]. Mice receiving 3% DSS were pre-treated for
three days, and mice receiving 5% DSS were pre-treated for five
days. Once infections were performed, the mice were provided
with regular drinking water for the course of the experiment.
Sodium bicarbonate was added to virus to make 5% mixtures
immediately prior to oral infections [23]. Mice were housed in
individual cages and feces were collected at 24-hour intervals with
subsequent bedding changes. A combination of moist, freshly
acquired feces and dry feces were combined to generate the fecal
samples for the population diversity assay. For kinetics of viral
shedding experiments (Figure 4), fresh feces were harvested from
each mouse. For Evan’s Blue dye transit experiments (Figure 4A),
feces were weighed, resuspended in 6 volumes of PBS, freeze-
thawed three times, and samples were centrifuged at 13,000 rpm
for 1 minute. ‘‘Evan’s Blue Score’’ was determined by assessing
the level of blue color in the feces: slightly blue=1, light blue=2,
moderate blue=3, dark blue=4, intense blue=5. Upon eutha-
nasia, blood, stomach, small intestine, colon, and brain were
harvested and stored at 280uC prior to use. During tissue
harvests, lumenal contents were removed from gut tissues.
Sample Processing and Hybridization-based Viral
Diversity Assay
Tissues (brain, stomach, small intestine, colon) were homogenized
under liquid nitrogen using a mortar and pestle. For brain RNA
extractions, 1 ml of TRIZOL (Invitrogen, Carlsbad, CA) was added
to approximately 300mg of tissue, and extractions and RT-PCR
wereperformedaspreviouslydescribed [4].BN2 antisense primer59
ATGCTTTCAAGCATCTGACCTAACC 39 and NdeI sense
primer 59 AAACTGTTGGTGTCATATGCGCCTCCTGGAG
39 were used for RT-PCR and PCR. To amplify virus from tissues,
homogenized tissues were weighed and resuspended in 3 volumes of
PBS+ (16PBS supplemented with 100 mg/ml MgCl2 and CaCl2),
andfreeze-thawed3times.Feceswereweighed,resuspendedinPBS,
and freeze-thawed three times. Each tissue slurry was dounce
homogenized and centrifuged at 13,000 rpm for 1 minute, and
supernatants were kept as virus stocks. To limit microbial
contamination, virus from gut samples (stomach, small intestine,
colon, and feces) were chloroform extracted by adding 1/10 volume
of chloroform, centrifuged at 13,000 rpm for 2 minutes, and the
supernatant was kept as the virus stock. Virus was amplified for 2–3
rounds of replication (12–16 hours) at 37uCi nH e L ac e l l sa n dt h e
cells were harvested, resuspended in 50–100 mlo fP B S +,f r e e z e -
thawed, and kept as amplified virus stock. Half of the amplified virus
stock was added to 1ml of TRIZOL for RNA extractions and RT-
PCR. PCR was performed in quadruplicate and products were
combinedbeforetheywere run on anagarosegelandquantitated by
standards of known concentrations. These concentrations were used
to normalize the amount of PCR product blotted to 50–100 ng of
PCR product for each sample. DNA was blotted onto Hybond N+
membranes (GE Healthcare, Buckinghamshire, UK) using a 96-well
vacuum manifold, and membranes were pre-hybridized and
hybridized following standard procedures [54]. Optimal hybridiza-
tion annealing temperature was empirically determined to be 59uC
(data not shown). Probes were made by kinase treatment of specific
primers (see Figure S1) with [c-
32P] ATP and excess nucleotides
were removed with the Qiagen Nucleotide Removal kit (Qiagen,
Valencia, CA) [4]. Membranes were exposed to PhosphorImager
screens and scanned by Stormscan. Scanned blots were normalized
by comparison of equivalently loaded products of perfectly matched
PCR product to probe or mismatched PCR products to probe. Blot
image intensities wereadjustedsuchthat anyapparentmismatch dot
was no longer visible, thus eliminating the minimal level of cross-
reactivityoftheprobeswithnon-matchedPCRproducts(Figure1E).
Accession Number
The Genbank (http://www.ncbi.nlm.nih.gov/entrez) accession
number for serotype 1 poliovirus (Mahoney strain) is NC002058.
Supporting Information
Figure S1 Oligonucleotide probe sequences for detection of
individual virus pool members.
Found at: doi:10.1371/journal.ppat.1000082.s001 (0.40 MB PDF)
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Figure S3 Distribution of pool members in mouse tissues.
Found at: doi:10.1371/journal.ppat.1000082.s003 (0.25 MB PDF)
Figure S4 Viral diversity in tissues harvested at early time
points.
Found at: doi:10.1371/journal.ppat.1000082.s004 (2.58 MB TIF)
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